A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
Clinical trial NCT05660265 · TERMINATED
Trial details
- NCT number
- NCT05660265
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-26
- Primary completion
- 2025-09-22
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.